cytochrome P450 family 24 subfamily A member 1Genealiases: CP24 · CYP24 · HCAI · HCINF1 · P450-CC24
Q-omics provides the consensus-scored CYP24A1 profile across patient tissues and cancer cell-line models. CYP24A1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, CYP24A1 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, CYP24A1 RNA expression shows 14,882 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, KICH, and THYM as cancer lineages where CYP24A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP24A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP24A1 survival associations across molecular data types. CYP24A1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP24A1 RNA expression–survival associations across cancer types. High CYP24A1 expression shows unfavorable associations in UVM, LUAD, ACC and OV, but favorable associations in BRCA and UCEC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for CYP24A1 RNA expression.
This table summarizes CYP24A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CYP24A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP24A1 shows lower tumor expression in KICH, KIRC and BRCA and higher tumor expression in LUAD, LUSC and BLCA. The KICH box plot shows higher CYP24A1 RNA expression in normal versus tumor tissue (log2 FC = −3.841, t-test p < 0.001).
This table shows molecular features associated with CYP24A1 in patient tissues and cancer cell lines. In patient samples, CYP24A1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP24A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
